A detailed history of Mackenzie Financial Corp transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Mackenzie Financial Corp holds 18,232 shares of ACAD stock, worth $296,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,232
Previous 19,900 8.38%
Holding current value
$296,634
Previous $323,000 13.31%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.14 - $19.14 $25,253 - $31,925
-1,668 Reduced 8.38%
18,232 $280,000
Q2 2024

Aug 14, 2024

SELL
$14.62 - $18.42 $553,206 - $696,994
-37,839 Reduced 65.53%
19,900 $323,000
Q1 2024

May 10, 2024

BUY
$17.79 - $30.86 $84,680 - $146,893
4,760 Added 8.98%
57,739 $1.07 Million
Q4 2023

Jan 30, 2024

BUY
$20.78 - $31.77 $819,978 - $1.25 Million
39,460 Added 291.89%
52,979 $1.66 Million
Q3 2023

Oct 25, 2023

SELL
$20.84 - $33.47 $211,380 - $339,486
-10,143 Reduced 42.87%
13,519 $281,000
Q2 2023

Aug 03, 2023

BUY
$17.8 - $25.65 $183,785 - $264,836
10,325 Added 77.42%
23,662 $566,000
Q1 2023

Apr 24, 2023

SELL
$16.32 - $20.92 $20,465 - $26,233
-1,254 Reduced 8.59%
13,337 $251,000
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $272,938 - $358,087
-19,221 Reduced 56.85%
14,591 $232,000
Q3 2022

Oct 07, 2022

SELL
$14.11 - $18.27 $11,358 - $14,707
-805 Reduced 2.33%
33,812 $553,000
Q2 2022

Aug 10, 2022

BUY
$13.01 - $27.22 $203,918 - $426,646
15,674 Added 82.74%
34,617 $488,000
Q1 2022

May 13, 2022

BUY
$20.94 - $27.5 $163,017 - $214,087
7,785 Added 69.77%
18,943 $459,000
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $187,342 - $302,270
11,158 New
11,158 $260,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.63B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.